Gawande, still mum on plans for new health venture, pulls out of major health conference

first_imgBusiness Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. What’s included? National Technology Correspondent Casey covers the use of artificial intelligence in medicine and its underlying questions of safety, fairness, and privacy. He is the co-author of the newsletter STAT Health Tech. By Casey Ross Jan. 17, 2019 Reprints If ever there was a celebrity in health care, it was Dr. Atul Gawande. He frequented the biggest stages in media and medicine. He gave TED talks, interviews with top journalists, and moderated a discussion on health innovation with President Obama. His books and essays for the New Yorker made him not just a sought-after speaker, but the unofficial leader of medicine’s less-is-more movement.At least, until six months ago, when he became a CEO. Since drawing tremendous attention when he was dispatched by the leaders of Amazon, JPMorgan Chase, and Berkshire Hathaway to create a venture with the long-term goal of transforming health care, Gawande has virtually disappeared from the public eye. He isn’t giving interviews or releasing information about the direction of the new company. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More [email protected] What is it?center_img Dr. Atul Gawande Aram Boghosian for The Boston Globe @caseymross Casey Ross STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. GET STARTED About the Author Reprints Gawande, still mum on plans for new health venture, pulls out of major health conference Tags BostonHIMSShospitalsinsuranceSTAT+last_img

Leave a Reply

Your email address will not be published. Required fields are marked *